Payment overview · 2025
General Payments
$321.12
18 reported records · 6 companies
Healthcare provider profile · identity verified
John Hunter Leigh, D.O.
Allopathic & Osteopathic Physicians|General Practice · GREER, SC · NPI 1295706000
Verified facts
What the public records show
CMS Open Payments records show John Hunter Leigh, D.O. received $321.12 in general payments during 2025 across 18 reported records.
Novo Nordisk Inc accounted for 47.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Kerendia, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $152.03 | 47.3% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.79 | 18.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.59 | 13.3% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $32.51 | 10.1% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.19 | 5.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.01 | 5.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $321.12 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $133.58 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $65.26 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.91 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $42.59 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $42.59 | 3 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $37.05 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.19 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 137 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 252 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
64 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 33 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
252 | 52 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1123 | 315 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 884 | 250 |
| Amlodipine Besylate | Amlodipine Besylate | 608 | 181 |
| Levothyroxine Sodium | Levothyroxine Sodium | 578 | 149 |
| Omeprazole | Omeprazole | 416 | 126 |
| Metoprolol Succinate | Metoprolol Succinate | 400 | 115 |
| Lisinopril | Lisinopril | 392 | 114 |
| Ezetimibe | Ezetimibe | 327 | 102 |
| Metformin Hcl Er | Metformin Hcl | 319 | 95 |
| Jardiance | Empagliflozin | 275 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 95 |
| Indapamide | Indapamide | 262 | 80 |
| Ozempic | Semaglutide | 252 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 231 | 74 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 230 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 225 | 71 |
| Losartan Potassium | Losartan Potassium | 225 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 78 |
| Metformin Hcl | Metformin Hcl | 211 | 61 |
| Montelukast Sodium | Montelukast Sodium | 209 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 202 | 56 |
| Allopurinol | Allopurinol | 198 | 58 |
| Trazodone Hcl | Trazodone Hcl | 198 | 58 |
| Pioglitazone Hcl | Pioglitazone Hcl | 176 | 46 |
| Gabapentin | Gabapentin | 174 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 169 | 47 |
| Sertraline Hcl | Sertraline Hcl | 164 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 38 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 147 | 41 |
| Alendronate Sodium | Alendronate Sodium | 142 | 40 |
| Farxiga | Dapagliflozin Propanediol | 137 | 33 |
| Potassium Chloride | Potassium Chloride | 135 | 37 |
| Trulicity | Dulaglutide | 130 | 29 |
| Carvedilol | Carvedilol | 129 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 128 | 39 |
| Finasteride | Finasteride | 125 | 39 |
| Eliquis | Apixaban | 123 | 33 |
| Famotidine | Famotidine | 112 | 33 |
| Torsemide | Torsemide | 110 | 37 |
| Chlorthalidone | Chlorthalidone | 100 | 31 |
| Telmisartan | Telmisartan | 100 | 26 |
| Azelastine Hcl | Azelastine Hcl | 91 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 87 | 24 |
| Spironolactone | Spironolactone | 84 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 25 |
| Valsartan | Valsartan | 80 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 79 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 16 |
| Mounjaro | Tirzepatide | 71 | 16 |
| Simvastatin | Simvastatin | 66 | 21 |
| Synthroid | Levothyroxine Sodium | 64 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 28 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 19 |
| Bupropion Xl | Bupropion Hcl | 60 | 18 |
| Furosemide | Furosemide | 57 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 17 |
| Glimepiride | Glimepiride | 53 | 17 |
| Buspirone Hcl | Buspirone Hcl | 51 | 18 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 13 |
| Warfarin Sodium | Warfarin Sodium | 49 | 11 |
| Benazepril Hcl | Benazepril Hcl | 47 | 13 |
| Xarelto | Rivaroxaban | 45 | 14 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 44 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 44 | 21 |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 42 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Pregabalin | Pregabalin | 39 | suppressed |
| Celecoxib | Celecoxib | 38 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 22 |
| Rybelsus | Semaglutide | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | 11 |
| Meclizine Hcl | Meclizine Hcl | 32 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 30 | 16 |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 30 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | 11 |
| Ondansetron Odt | Ondansetron | 27 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 27 | suppressed |
| Testosterone | Testosterone | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 21 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lidocaine | Lidocaine | 21 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Prednisone | Prednisone | 19 | 13 |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 15 |
| Dexamethasone | Dexamethasone | 17 | 12 |
| Meloxicam | Meloxicam | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 13 |
| Estradiol | Estradiol | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Kerendia | Finerenone | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 12 |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $321.12 · 18 records | Novo Nordisk Inc | AIRSUPRA, Dexcom G6 Transmitter, FARXIGA, Kerendia, OTEZLA, Ozempic, REPATHA, Rybelsus, Tresiba, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error